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Topic: Prehospital use of ipratropium bromide paired with salbutamol as treatment for shortness of breath. 
Clinical Scenario: Two primary care paramedics respond code 4 for a 55 year old male patient severely short of breath. Questioning 
his wife reveals that the patient has chronic obstructive pulmonary disease (COPD), takes Ventolin (salbutamol) when necessary and 
takes Atrovent (ipratropium bromide) daily. He took his Atrovent today, but experienced sudden onset shortness of breath after 
walking up the flight of stairs in his home. 
PICO Question: In patients with shortness of breath from respiratory diseases, does the use of prehospital ipratropium bromide paired 
with salbutamol provide a better outcome than salbutamol treatment alone? 
Search Strategy: see Appendix 1 
Relevant Papers: eight relevant articles were found, but four were reviewed because they were most directly related to the topic 
Key Words: FVC: forced vital capacity, amount of air which can be forcibly exhaled from the lungs after taking a full breath in 
          FEV1: forced expiratory volume, volume of air exhaled in one second of forced expiration 
          ED: emergency department 
          COPD: chronic obstructive pulmonary disease 
          COAD: chronic obstructive airway disease 
 
Author, 
Date 
Population Design Outcomes Results Strengths/Weaknesses 
Davis, D., 
2005 
371 adult 
patients, 18 
years of age 
or older, 
transported to 
the 
University of 
California 
ED and 
treated for 
suspected 
reactive 
Prehospital 
retrospective 
study 
• Change in 
heart rate, 
respiratory 
rate, blood 
pressure 
and/or oxygen 
saturation. 
• Clinical 
improvement 
or 
deterioration 
Avg. change in vital signs, 
Albuterol alone cohort 
(n=192) 
• ∆HR: -3 bpm 
• ∆BP: -7mmHg 
• ∆resp. rate: 0 
• ∆SaO2: +8% 
• Improved clinical status: 
34% of pts 
Avg. change in vital signs, 
Albuterol/Ipratropium cohort 
(n=179) 
Strengths 
Used vitals as an objective 
way to obtain data of patient 
improvement. Fairly large 
sample size. Study could be 
reproduced in other regions. 
 
Weaknesses 
Retrospective design, so 
patients were not 
randomized to receive each 
treatment.  Data relies on 
airway 
disease 
(RAD). Pts 
were treated 
with either 
nebulized 
albuterol and 
ipratropium 
bromide or 
just albuterol. 
as assessed by 
paramedics. 
• ∆HR: -6 bpm 
• ∆BP: -10mmHg 
• ∆resp. rate: 
-4 breaths/min 
• ∆SaO2: +8% 
• Improved clinical status: 
33% of pts 
 
There was no statistically 
significant difference, p-value 
< 0.05, between groups. 
 
past EMS and ED records. 
Approximately one third of 
patients included in study 
were diagnosed with a 
cardiac etiology for their 
dyspnea. Analyzing 
treatment effect during short 
prehospital transport times 
does not indicate the longer-
term effects. 
 
Author, 
Date 
Population Design Outcomes Results Strengths/Weaknesses 
Moayyedi, 
P., 1995 
62 patients 
admitted to 
hospital for 
acute 
exacerbation 
of COPD. Pts 
treated with 
either 5mg 
nebulized 
salbutamol and 
500µg 
ipratropium 
bromide, or 
just 5mg 
salbutamol, 
both four times 
a day. 
 
Randomized 
controlled 
trial 
• Change in 
spirometric values 
(forced vital 
capacity and 
FEV1) on days 1, 
3, 7, 14 and then 
weekly and on the 
day of discharge. 
• Simple subjective 
symptom score 
recorded daily. Pts 
asked to report 
whether they feel 
better, worse, or 
the same as the 
day before. 
• Duration of 
hospital stay. 
Mean change in FEV1 
Salbutamol only 
• Day 1 – 3: +0.17 mL 
• Day 1 – 7: +0.21 mL 
• Day 1 – 14: +0.06 mL 
• Discharge: +0.23 mL 
Mean change in FVC 
Salbutamol only 
• Day 1 – 3: +0.25 mL 
• Day 1 – 7: +0.39 mL 
• Day 1 – 14: +0.33 mL 
• Discharge: +0.56 mL 
Mean change in FEV1 
Salbutamol + ipratropium 
bromide 
• Day 1 – 3: +0.05 mL 
• Day 1 – 7: +0.15 mL 
• Day 1 – 14: +0.26 mL 
Strengths 
Examines changes over 
time to get a better picture 
of the long-term effects of 
the two treatments. 
Extensive exclusion 
criteria to ensure minimal 
confounding variables. 
Spirometric values 
obtained at 1800 hrs each 
time. 
 
Weaknesses 
Small sample size, also 
restricted to patients with 
COPD.  
Some patients did receive 
other IV steroid and 
All pts were 
not taking 
nebulized 
bronchodilator
s at home, 
were 45 years 
of age or older, 
and had a 
history of 
smoking more 
than 10 pack 
years. 
• Numbers of days 
on nebulizer 
treatment. 
• Discharge: +0.15 mL 
Mean change in FVC 
Salbutamol + ipratropium 
bromide 
• Day 1 – 3: +0.04 mL 
• Day 1 – 7: +0.17 mL 
• Day 1 – 14: +0.62 mL 
• Discharge: +0.42 mL 
 
No statistically significant 
difference, p <0.05 
between groups. 
antibiotic medication, but 
study states there was no 
statistically significant 
difference between groups. 
 
Author, Date Population Design Outcomes Results Strengths/Weaknesses 
Koutsogiannis, 
Z., 2000 
50 adult patients 
admitted to the 
emergency 
department with 
COAD. Pts 
received 5mg 
nebulized 
salbutamol and 
500µg 
ipratropium 
bromide and 
250mg IV 
hydrocortisone at 
time=0. Then 
randomized to 
receive 5mg 
salbutamol and 
500µg 
ipratropium 
Prospective, 
randomised, 
double 
blind trial 
• Mean 
percent 
change in 
FEV1 
measured at 
time=0 and 
time=90 
mins. 
• Absolute 
change on 
pulmonary 
function test 
Mean percentage 
change in FEV1 
• comb. treatment: 
6.4% 
• salbutamol: 
18.6% 
• ipratropium: 
4.8% 
Mean absolute 
change on 
pulmonary function 
test 
• comb. treatment: 
0.06L 
• salbutamol: 
0.13L 
• ipratropium: 
0.023L 
 
Strengths  
Different perspective 
considering ipratropium bromide 
was given to both groups as an 
initial treatment, then studied 
subsequent treatments of 
ipratropium. 
Explains the cost of ipratropium 
bromide and the seemingly 
minimal benefits when paired 
with salbutamol in the 
prehospital environment. 
 
Weaknesses 
Small sample size and only one 
diagnostic tool used for 
comparison of improvement. 
Standard deviation in absolute 
change in FEV1 is large in all 
bromide, or 5mg 
salbutamol alone, 
or 500µg 
ipratropium 
bromide alone, at 
15min and 30min. 
No statistically 
significant difference 
between groups. 
groups, suggesting there are 
subgroups within the sample that 
may benefit from the combined 
treatment. 
 
Author, 
Date 
Population Design Outcomes Results Strengths/Weaknesses 
Lanes, S.F., 
1998 
1064 pts aged 
18 to 55 years 
admitted to the 
emergency 
department 
with acute 
asthma. Pts 
randomized for 
treatment of a 
combination of 
nebulized 
2.5mg 
salbutamol 
plus 0.5mg 
ipratropium 
bromide, or 
2.5mg 
salbutamol 
alone. 
Pooled 
analysis of 
three 
randomized 
double-
blinded 
clinical trials 
conducted in 
the United 
States, 
Canada and 
New 
Zealand. 
• FEV1 measured 
at baseline, 45 
mins and 90 
mins. Pts 
followed up for 
48h after 
hospital 
discharge for 
occurrence of 
asthma 
exacerbation 
and 
hospitalization. 
• Reduced risk of 
need for 
additional 
treatment, 
subsequent 
asthma 
exacerbations 
and 
hospitalizations 
Mean difference between 
FEV1 change from time=0 
 
Ipratropium + salbutamol 
45 minutes 
• CAN: 587mL 
• NZ: 461mL 
• US: 651mL 
90 minutes 
• CAN: 633mL 
• NZ: 519mL 
• US: 831mL 
 
Salbutamol 
45 minutes 
• CAN: 542mL 
• NZ: 369mL 
• US: 645mL 
90 minutes 
• CAN: 542mL 
• NZ: 416mL 
• US: 851mL 
Strengths 
Account for all 
differentiating factors in 
the populations studied. 
Extensively explains and 
accounts for all study 
biases, including the 
original claims of each of 
the studies, which did not 
coincide with the overall 
conclusions when 
looking at all three 
studies. 
Weaknesses 
Outcome of seemingly 
positive effects of the 
combination treatment 
was <10% of the overall 
improvement of FEV1 
from baseline, indicating 
only a small 
improvement. Also stated 
that the data could be 
Small improvement in lung 
function indicated for 
combination treatment. 
obscured by outliers in 
the U.S.A. study. 
 
 
Comments: 
One major challenge that presents with this PICO question is the specificity of observing prehospital, emergency medicine data of the 
benefits of pairing ipratropium bromide and salbutamol. None of the studies analyzed in this CAT occurred within the last 10 years, 
and took place in either the emergency department or longer in-hospital stays. Moayyedi et al. completed their study over several days 
until patient discharge, evaluating FEV1 and FVC, as well as some subjective symptom questions (1995). This prospective study 
produced no statistically significant difference between treatment groups, further suggesting that ipratropium bromide paired with 
salbutamol does not give any additional benefit to patients with SOB due to airway diseases. Contraindicative to these results, Lanes et 
al. examine FEV1 at 0 mins, 45 mins, and 90 mins after arrival in the ED (1998). A small improvement was noted for patients who 
received the combination treatment, as well as reduced risk for subsequent symptoms of asthma. The large total sample size and cross-
country meta-analysis study design enhances the efficacy of the results and the ability to detect small differences in data (Lanes et al. 
1998). Only one of the studies mentioned a reason for questioning the effect of the combination treatment. The cost of using a 
medication that does not seem to have significant benefit in prehospital treatment, is a factor to consider because that money can be 
put towards something else. Emergency medicine in Canada is always in need of improvements in equipment, education, community 
programs, and many other things. Though the cost of PCPs using ipratropium bromide may seem small, the savings of not using it 
over a year could have a significant benefit to another aspect of paramedicine. There is also always a risk of patients having adverse 
reactions to medications. So if the latest evidence-based medicine shows little to no benefit of the pairing of ipratropium bromide and 
salbutamol in the prehospital environment, it should be considered to be removed from PCP scope of practice. 
Consider: Why would you NOT change practice, based on these articles? 
Since these studies mainly look at short term treatment of ipratropium bromide and salbutamol, the long term effects of the 
combination is not well observed. Perhaps continuous treatment of the paired medications has a significant effect in patient 
presentation after several weeks. The use of the combination treatment in the prehospital environment could be beneficial for patients 
who are going to be prescribed these two medications and will be using them consistently from that point forward. Using it to treat 
these critical patients will theoretically begin their treatment at the earliest moment possible. 
 
Clinical Conclusion: 
The use of ipratropium bromide for shortness of breath due to chronic airway diseases, appears to be of little additional benefit than 
salbutamol treatment alone, in the prehospital environment. Paramedics should perhaps consider the costs of using the drugs paired 
together when deciding what to use to treat SOB. Salbutamol alone is a very effective way to dilate bronchioles, enhance ventilation 
and allow for reperfusion in a short period of time. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Appendix 1 
 
Back-sourcing used 
Nova Scotia EHS: Canadian Prehospital Evidence-Based Practice website used  
https://emspep.cdha.nshealth.ca/LOE.aspx?VProtStr=Asthma&VProtID=200 
 
 
 
 
 
 
 Key Word Results (CINAHL & EBSCO) Results (MEDLINE) 
S1 Ipratropium bromide/albuterol 246 626 
S2 Albuterol/ipratropium bromide 22 422 
S3 Ipratropium bromide/salbutamol 173 689 
S4 Salbutamol/ipratropium bromide 17 689 
S5 Salbutamol 318 11492 
S6 Albuterol 1363 10061 
S7 Ipratropium bromide 160 2233 
S8 Prehospital 11606 9338 
 S9 Pre hospital 1114 38437 
S10 Pre-hospital 710 3279 
S11 Out of hospital 5582 95408 
S12 S1 OR S3 249 724 
S13 S5 OR S6 1486 12220 
S14 S8 OR S9 OR S10 OR S11 17160 136985 
S15 S12 AND S13 AND S14 AND S7 1 9 
S16 S14 AND S7 52  
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